URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
Phase of Trial: Phase IV
Latest Information Update: 20 Oct 2015
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms URGE-PD
- 06 Mar 2015 Status changed from active, no longer recruiting to completed.
- 27 Jun 2014 Planned End Date changed from 1 Mar 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 27 Jun 2014 Planned primary completion date changed from 1 Mar 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History